Curated for Orthogate.org Members

CLINICAL OVERVIEW

Providence Medical Technology, Inc. has secured FDA 510(k) clearance for the CORUS™ PCSS 3D-T (Posterior Cervical Stabilization System 3D-Printed Titanium), bringing advanced additive manufacturing and porous biomaterial engineering to its proprietary Total Segmental Fusion (TSF) platform. Indicated as an adjunct to posterior cervical arthrodesis across C3–C7 for cervical degenerative disc disease (DDD), the system pairs the clinically validated, nonsegmental mechanical fixation of the original CORUS™ PCSS with an osteoconductive, 3D-printed porous titanium lattice. By stabilizing the posterior column through rigid bilateral facet joint fixation and simultaneous intra-articular fusion, the system addresses the biomechanical shortcomings of isolated anterior reconstructions in high-risk patients.

The clinical rationale of the Total Segmental Fusion philosophy targets the persistent challenge of pseudarthrosis in multilevel anterior cervical discectomy and fusion (ACDF). In 3-level and 4-level ACDFs, non-union rates have historically approached 20% to 30%, largely attributable to substantial cantilever bending moments, axial subsidence of interbody cages, and persistent micromotion at posterior facet joints. While open posterior lateral mass screw-and-rod fixation provides rigid stabilization, it entails extensive subperiosteal stripping, denervation of posterior paraspinal musculature, protracted operative times, and elevated blood loss. CORUS™ PCSS 3D-T provides a minimally invasive, facet-sparing alternative: through percutaneous or mini-open access, the facet joints are decorticated, packed with autologous bone graft, and stabilized with 3D-printed porous titanium implants secured by integrated cortical screws, creating instantaneous 360-degree segmental rigidity.

The 3D-T implant architecture incorporates an interconnected porous titanium lattice engineered to mimic the biomechanical modulus and architecture of human trabecular bone. Featuring a porosity gradient with pore diameters ranging between 300 and 600 μm and extensive nano-scale surface roughness, the 3D-printed structure accelerates osteoblast adhesion, osteogenesis, and vascular infiltration throughout the implant interior. Unlike traditional solid PEEK or smooth machined titanium spacers that rely solely on external graft packing, the 3D-T implant facilitates through-growth osseointegration across the facet joint space, establishing permanent biological joint arthrodesis.

REGULATORY & EVIDENCE PATHWAY

• Regulatory Basis: FDA 510(k) clearance granted in October 2026 under 21 CFR 888.3075 (Posterior cervical spinal fixation system; Product Code: NKG / KWP), establishing mechanical equivalence and biological safety relative to predicate CORUS™ PCSS and CAVUX® facet devices.
• Supporting Evidence: The CORUS™ platform is anchored by robust Level 1 clinical evidence from the prospective, multicenter randomized controlled FUSE trial. In high-risk patients undergoing multilevel cervical arthrodesis, the addition of posterior facet stabilization to ACDF resulted in statistically significant reductions in pseudarthrosis and lower revision surgery rates compared to anterior-only cohorts at 24 months.
• Key Data Points: Biomechanical fatigue, static compression-shear, dynamic torsion, and screw-pullout bench testing (ASTM F1717 / ASTM F2077) demonstrated that the 3D-printed titanium construct achieves immediate construct stiffness comparable to multi-level posterior rod constructs, while clinical registries document fusion rates exceeding 95% at 12 to 24-month follow-up without implant migration.

SURGICAL WORKFLOW IMPACT

The CORUS™ PCSS 3D-T system utilizes single-use, sterile-packaged surgical instrument sets designed for tissue-preserving posterior delivery. Using fluoroscopic guidance, surgeons place guide pins into the targeted facet joints, decorticate the articular cartilage with specialized decorticators, introduce autograft or allograft, and insert the porous titanium implant with integrated screw fixation.

This streamlined workflow adds only 15 to 25 minutes of operative time following an anterior procedure. Compared to traditional lateral mass screw fixation, it eliminates the necessity for extensive paraspinal muscle dissection, reduces intraoperative blood loss, and mitigates the incidence of persistent postoperative axial neck pain and proximal junctional kyphosis (PJK), making it highly viable in high-throughput hospital settings and ambulatory surgical centers (ASCs).

COMPETITIVE LANDSCAPE

CORUS™ PCSS 3D-T occupies a unique niche against traditional posterior cervical lateral mass screw-and-rod fixation systems (e.g., Medtronic Vertex® / Infinity™, DePuy Synthes Mountaineer® / Symphony™, and Globus Medical Ellipse®), as well as anterior standalone multi-level plating systems.

Whereas conventional posterior screw-and-rod constructs require broad surgical exposure spanning multiple segments to stabilize 2 to 4 levels—often leading to significant muscle atrophy, blood loss, and prolonged hospitalization—CORUS™ PCSS 3D-T enables level-specific, joint-sparing stabilization through mini-open incisions. Furthermore, compared to smooth PEEK facet spacers, its 3D-printed porous titanium matrix provides direct osseointegrative capacity and superior biological fusion potential.

CLINICAL SIGNIFICANCE FOR ORTHOGATE MEMBERS

For cervical spine attendings, fellows, and complex spine reconstructive surgeons, CORUS™ PCSS 3D-T represents an evidence-backed solution for the highest-risk cervical fusion cohorts. In patients with nicotine dependence, uncontrolled diabetes, osteopenia, revision pseudarthrosis, or long-segment 3- and 4-level anterior reconstructions, relying on anterior-only fixation carries an unacceptably high rate of mechanical failure. Adding CORUS™ PCSS 3D-T achieves circumferential Total Segmental Fusion with minimal morbidity, protecting the anterior graft from subsidence and delivering superior fusion security without the morbidity of traditional open posterior plating.

Sources:

• OrthoSpineNews: Providence Medical Technology Receives FDA 510(k) Clearance for CORUS™ PCSS 3D-T
• Providence Medical Technology — Total Segmental Fusion Platform
• U.S. FDA 510(k) Premarket Notification Database